Evidence map›Paper›PMID 21393384›Full record

ArticleProtein engineering, design & selection : PEDS2011

Dissecting key residues in folding and stability of the bacterial immunity protein 7.

Stuart Knowling, Alice I Bartlett, Sheena E Radford

Abstract read
In one paragraph

Article in Protein engineering, design & selection : PEDS, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Stuart KnowlingAstbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, UK.
Alice I Bartlett
Sheena E Radford

Funding

Biotechnology and Biological Sciences Research Council BB/F01614X/1Wellcome Trust 045223Wellcome Trust 075099
6 · The paper itself

Abstract

The small four-helix immunity protein, Im7, has previously been shown to fold via a compact intermediate containing three of the four native helices. The short, six-residue helix III only docks onto the developing Im7 structure after the rate-limiting second transition state has been traversed. Previous work demonstrated that mutation of the helix III sequence can be used to trap the protein in the on-pathway intermediate ensemble at equilibrium. Here the role played by individual residues in the native helix III sequence in locking Im7 into a stable native structure is further examined. This work commenced with an Im7 sequence trapped in the partially folded state by substitution of the six residues in helix III with a polyglycine sequence. Biophysical analysis of variants in which individual residues from the native helix III sequence, and combinations of these residues, were introduced into this background demonstrated a critical requirement for three residues, Leu 53, Ile 54 and Tyr 55, to lock Im7 into its unique native structure. The results demonstrate a stringent constraint on the evolution of the Im7 helix III sequence rationalizing its high-sequence identity in the fold family. Thus, Leu 53 and Ile 54 provide crucial stabilizing interactions in the hydrophobic core of native Im7, while Tyr 55 is required for both stability and function. In contrast, Tyr 56 is critical for colicin binding and has no role in maintaining a stable native fold.

Indexed as

Amino Acid SequenceCarrier ProteinsCircular DichroismEscherichia coli ProteinsHydrophobic and Hydrophilic InteractionsModels, MolecularMolecular Sequence AnnotationProtein EngineeringProtein FoldingProtein StabilitySequence AlignmentSpectrometry, FluorescenceStructure-Activity RelationshipThermodynamicsCarrier ProteinsE colicin-binding immunity protein Im7, E coliEscherichia coli Proteins

Identifiers

PMID21393384
PMCPMC3092693

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.